The Potential Drug Target DLGAP2 (G9228)

Target Name: DLGAP2

NCBI ID: G9228

DLGAP2

The Potential Drug Target DLGAP2

DLGAP2 (DAPK1 gene) is a gene that encodes a protein known asDLGAP2 (DLGP2_HUMAN). DLGAP2 is a protein that is expressed in many tissues throughout the body, including the brain, heart, and kidneys. It is a member of theDLGAP family, which includes several similar proteins that are involved in the regulation of cellular processes such as cell division, metabolism, and stress responses.

The DLGAP2 gene was identified as a potential drug target (or biomarker) due to its involvement in several cellular processes that are associated with various diseases, including cancer, neurodegenerative diseases, and systemic inflammation. The DLGAP2 protein has also been shown to play a role in several diseases, including ALS, a progressive neurodegenerative disease, and neuroimmune disorders.

One of the key features of the DLGAP2 protein is its ability to interact with several different protein partners, including otherDLGAPs, HDACs (hypoxia-inducible transmembrane proteins), and recruiters. These interactions allow DLGAP2 to regulate cellular processes such as cell division, metabolism , and stress responses. The ability of DLGAP2 to interact with multiple protein partners also makes it a potential drug target, as it may be difficult to target a single protein with small molecules.

Another feature of the DLGAP2 protein is its ability to induce apoptosis (programmed cell death) in certain cell types. Apoptosis is a natural process that helps the body remove damaged or unnecessary cells. However, in diseases such as cancer, apoptosis may be disrupted, leading to the development of cancer cells. The ability of DLGAP2 to induce apoptosis suggests that it may be a useful target for cancer treatments.

In addition to its involvement in apoptosis, the DLGAP2 protein has also been shown to play a role in several other cellular processes, including cell signaling, DNA replication, and metabolism. The precise functions of the DLGAP2 protein are not well understood, but its involvement in these processes suggest that it may be a useful target for drugs that target cellular processes that are associated with various diseases.

The utility of the DLGAP2 protein as a drug target or biomarker is further supported by its expression in several diseases, including cancer, neurodegenerative diseases, and systemic inflammation. For example, studies have shown that high levels of DLGAP2 are associated with poor prognosis in patients with pancreatic cancer, a highly aggressive form of cancer. Similarly, the DLGAP2 protein has been shown to be involved in the development and progression of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

In conclusion, the DLGAP2 protein is a promising drug target or biomarker due to its involvement in several cellular processes that are associated with various diseases. Its ability to interact with multiple protein partners and induce apoptosis suggests that it may be a useful target for drugs that target cellular processes that are disrupted in diseases such as cancer, neurodegenerative diseases, and systemic inflammation. Further research is needed to fully understand the functions of the DLGAP2 protein and its potential as a drug target or biomarker.

Protein Name: DLG Associated Protein 2

Functions: May play a role in the molecular organization of synapses and neuronal cell signaling. Could be an adapter protein linking ion channel to the subsynaptic cytoskeleton. May induce enrichment of PSD-95/SAP90 at the plasma membrane

The "DLGAP2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DLGAP2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets